JP6917379B2 - 8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体 - Google Patents

8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体 Download PDF

Info

Publication number
JP6917379B2
JP6917379B2 JP2018536384A JP2018536384A JP6917379B2 JP 6917379 B2 JP6917379 B2 JP 6917379B2 JP 2018536384 A JP2018536384 A JP 2018536384A JP 2018536384 A JP2018536384 A JP 2018536384A JP 6917379 B2 JP6917379 B2 JP 6917379B2
Authority
JP
Japan
Prior art keywords
alkyl
unsaturated
phenyl
substituted
diazaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018536384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501932A (ja
JP2019501932A5 (https=
Inventor
キューネルト・スヴェン
ケーニヒス・レーネ・ミヒャエル
クレス・アヒム
ヴェゲルト・アニータ
ラトクリッフェ・パウル
ヨストック・ルート
コッホ・トーマス
リンツ・クラウス
シュレーダー・ヴォルフガング
Original Assignee
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング filed Critical グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング
Publication of JP2019501932A publication Critical patent/JP2019501932A/ja
Publication of JP2019501932A5 publication Critical patent/JP2019501932A5/ja
Application granted granted Critical
Publication of JP6917379B2 publication Critical patent/JP6917379B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2018536384A 2016-01-13 2017-01-13 8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体 Expired - Fee Related JP6917379B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16151015.1 2016-01-13
EP16151015 2016-01-13
PCT/EP2017/025008 WO2017121650A1 (en) 2016-01-13 2017-01-13 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Publications (3)

Publication Number Publication Date
JP2019501932A JP2019501932A (ja) 2019-01-24
JP2019501932A5 JP2019501932A5 (https=) 2021-03-18
JP6917379B2 true JP6917379B2 (ja) 2021-08-11

Family

ID=55129636

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536384A Expired - Fee Related JP6917379B2 (ja) 2016-01-13 2017-01-13 8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体

Country Status (26)

Country Link
US (7) US20170197949A1 (https=)
EP (1) EP3402782B1 (https=)
JP (1) JP6917379B2 (https=)
KR (1) KR20180097734A (https=)
CN (1) CN108602778B (https=)
AR (1) AR107359A1 (https=)
AU (1) AU2017206911B2 (https=)
BR (1) BR112018014301B1 (https=)
CA (1) CA3011182A1 (https=)
CL (1) CL2018001909A1 (https=)
CO (1) CO2018008450A2 (https=)
CY (1) CY1123366T1 (https=)
DK (1) DK3402782T3 (https=)
EA (1) EA034898B1 (https=)
EC (1) ECSP18060875A (https=)
ES (1) ES2821969T3 (https=)
HR (1) HRP20201660T1 (https=)
HU (1) HUE051642T2 (https=)
IL (1) IL260488B (https=)
LT (1) LT3402782T (https=)
MX (1) MX379359B (https=)
PT (1) PT3402782T (https=)
RS (1) RS60855B1 (https=)
SI (1) SI3402782T1 (https=)
TW (1) TWI654181B (https=)
WO (1) WO2017121650A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3402782T1 (sl) 2016-01-13 2020-11-30 Grunenthal Gmbh 8-amino-2-okso-1,3-diaza-spiro-(4,5)-dekanski derivati
JP6854823B2 (ja) 2016-01-13 2021-04-07 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 3−(カルボキシメチル)−8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体
EP3722284B1 (en) 2016-01-13 2025-01-22 Grünenthal GmbH 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
PL3402783T3 (pl) 2016-01-13 2020-08-24 Grünenthal GmbH Pochodne 3-(karboksyetylo)-8-amino-2-okso-1,3-diazaspiro-[4.5]-dekanu
US20170197947A1 (en) 2016-01-13 2017-07-13 Gruenenthal Gmbh 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives
WO2019039852A1 (ko) 2017-08-22 2019-02-28 주식회사 엘지화학 방열 소재 디스펜싱 장치의 결정방법
JP7446316B2 (ja) 2019-01-11 2024-03-08 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換ピロリジンアミドiii
CN110092790B (zh) * 2019-06-11 2020-07-24 东北农业大学 一种生物碱类化合物及其制备方法和应用
US20240400537A1 (en) 2023-04-25 2024-12-05 Gruenenthal Gmbh Cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
KR100855204B1 (ko) 2001-04-18 2008-09-01 유로-셀티크 소시에떼 아노뉨 노시셉틴 유사체
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
DE10135636A1 (de) * 2001-07-17 2003-02-06 Gruenenthal Gmbh Substituierte 4-Aminocyclohexanole
DE10210195B4 (de) 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
WO2004005293A2 (en) 2002-07-05 2004-01-15 Targacept, Inc. N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US20080287478A1 (en) 2003-05-23 2008-11-20 Lars Bo Laurenborg Hansen Nociceptin Analogues and Uses Thereof
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
DE102005023784A1 (de) 2005-05-19 2006-11-30 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102006019597A1 (de) 2006-04-27 2007-10-31 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP5079011B2 (ja) 2006-10-19 2012-11-21 エフ.ホフマン−ラ ロシュ アーゲー 糖尿病のための11β−HSD1阻害剤としてのイミダゾロン及びイミダゾリジノン誘導体
JP5490677B2 (ja) 2007-04-09 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのorl−1受容体リガンドとしての1,3,8−三置換−1,3,8−トリアザ−スピロ[4.5]デカン−4−オン誘導体
ES2464102T3 (es) * 2008-03-27 2014-05-30 Grünenthal GmbH Derivados de 4-aminociclohexano sustituidos
TW201038572A (en) 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
WO2010151815A2 (en) 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式-四氫-螺旋(環己烷-1,1’-吡啶[3,4-b]吲哚)-4-胺-衍生物
EP2938341B1 (en) * 2012-12-31 2018-09-05 Sunovion Pharmaceuticals Inc. Heterocyclic compounds and methods of use thereof
JP6643545B2 (ja) * 2014-03-14 2020-02-12 ラクオリア創薬株式会社 Trpm8拮抗剤としてのアザスピロ誘導体
WO2015192039A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Heterocyclic morphinan derivatives and use thereof
EP3722284B1 (en) 2016-01-13 2025-01-22 Grünenthal GmbH 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
SI3402782T1 (sl) 2016-01-13 2020-11-30 Grunenthal Gmbh 8-amino-2-okso-1,3-diaza-spiro-(4,5)-dekanski derivati
TWI730032B (zh) 2016-01-13 2021-06-11 美商必治妥美雅史谷比公司 作為rock抑制劑之螺庚烷水楊酸醯胺及相關化合物
PL3402783T3 (pl) 2016-01-13 2020-08-24 Grünenthal GmbH Pochodne 3-(karboksyetylo)-8-amino-2-okso-1,3-diazaspiro-[4.5]-dekanu
US10822385B2 (en) 2016-01-13 2020-11-03 Novo Nordisk A/S EGF(A) analogues with fatty acid substituents
JP6854823B2 (ja) 2016-01-13 2021-04-07 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 3−(カルボキシメチル)−8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体
US20170197947A1 (en) 2016-01-13 2017-07-13 Gruenenthal Gmbh 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives

Also Published As

Publication number Publication date
TW201730155A (zh) 2017-09-01
AU2017206911B2 (en) 2020-07-09
EA201891608A1 (ru) 2019-01-31
WO2017121650A1 (en) 2017-07-20
KR20180097734A (ko) 2018-08-31
RS60855B1 (sr) 2020-10-30
AU2017206911A1 (en) 2018-08-30
US20200399255A1 (en) 2020-12-24
JP2019501932A (ja) 2019-01-24
CO2018008450A2 (es) 2018-09-20
TWI654181B (zh) 2019-03-21
PT3402782T (pt) 2020-10-01
AR107359A1 (es) 2018-04-25
US20190375738A1 (en) 2019-12-12
HUE051642T2 (hu) 2021-03-01
DK3402782T3 (da) 2020-09-28
ECSP18060875A (es) 2018-08-31
MX379359B (es) 2025-03-11
CY1123366T1 (el) 2021-12-31
CL2018001909A1 (es) 2018-10-19
BR112018014301A2 (pt) 2018-12-11
CN108602778B (zh) 2021-12-10
US20230183222A1 (en) 2023-06-15
BR112018014301B1 (pt) 2023-10-31
NZ745186A (en) 2024-05-31
IL260488B (en) 2021-09-30
EP3402782B1 (en) 2020-07-29
US20210179595A1 (en) 2021-06-17
LT3402782T (lt) 2020-10-12
SI3402782T1 (sl) 2020-11-30
CA3011182A1 (en) 2017-07-20
US10793556B2 (en) 2020-10-06
HRP20201660T1 (hr) 2021-03-05
EP3402782A1 (en) 2018-11-21
ES2821969T3 (es) 2021-04-28
US20170197949A1 (en) 2017-07-13
US20190100515A1 (en) 2019-04-04
MX2018008645A (es) 2018-11-19
CN108602778A (zh) 2018-09-28
US20180273516A1 (en) 2018-09-27
EA034898B1 (ru) 2020-04-03

Similar Documents

Publication Publication Date Title
JP6917379B2 (ja) 8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体
JP7148665B2 (ja) 3-(カルボキシメチル)-8-アミノ-2-オキソ-1,3-ジアザ-スピロ-[4.5]-デカン誘導体
ES2797904T3 (es) Derivados de 3-((hetero)aril)alquil-8-amino-2-oxo-1,3-diazaespiro-[4.5]-decano
JP7148660B2 (ja) 3-((ヘテロ-)アリール)-8-アミノ-2-オキソ-1,3-ジアザ-スピロ-[4.5]-デカン誘導体
JP6854823B2 (ja) 3−(カルボキシメチル)−8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体
HK40035886A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260545B (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260545A1 (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260461A1 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260461B (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260472A1 (en) 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260472B (en) 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260528B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260528A1 (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EA045034B1 (ru) Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро-[4,5]-декана

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200110

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201216

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210630

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210719

R150 Certificate of patent or registration of utility model

Ref document number: 6917379

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees